Peripheral neuropathy in chronic occupational inorganic lead exposure : A clinical and electrophysiological study by Rubens, O. et al.
Peripheral neuropathy in chronic occupational
inorganic lead exposure: a clinical and
electrophysiological study
O Rubens, I Logina, I Kravale, M Eglîte, M Donaghy
Abstract
Background and objectives—Traditionally
the neuromuscular disorder associated
with lead poisoning has been purely motor.
This study assessed peripheral nerve func-
tion clinically and electrophysiologically in
46 patients with neuropathic features out of
a total population of 151 workers with
raised blood and/or urinary lead concen-
trations.
Results—Average duration of occupa-
tional exposure for the neuropathic group
ranged from 8–47 years (mean 21.7). Their
mean blood lead concentration (SD) was
63.9 (18.3) µg/dl (normal <40), urinary
lead 8.6 (3.3) µg/dl (normal<5.0), urinary
coproporphyrins 66.7 (38.4) µg/g creati-
nine (20–80), urinary aminolaevulinic acid
1.54 (0.39) mg/g creatinine (0.5–2.5). All 46
had distal paraesthesiae, pain, impaired
pin prick sensation, diminished or absent
ankle jerks, and autonomic vasomotor or
sudomotor disturbances. Reduced vibra-
tion sensation and postural hypotension
were present in all 20 studied. None of
these 46 patients had motor anormalities.
Motor conduction velocity and compound
muscle action potential amplitudes were
normal, with marginally prolonged distal
motor latencies. Sensory nerve action
potential amplitudes lay at the lower end
of the normal range, and the distal
sensory latencies were prolonged. No
direct correlation was found between the
biochemical variables, and the clinical or
electrophysiological data.
Conclusions—One additional patient was
seen with shorter term exposure to lead
fumes with subacute development of col-
icky abdominal pain, severe limb weak-
ness, and only minor sensory symptoms.
Unlike the patients chronically exposed to
lead, he had massively raised porphyrins
(aminolaevulinic acid 21 mg/g creatinine,
coproporhyrins 2102 µg/g creatinine). Pa-
tients with unusually long term inorganic
lead exposure showed mild sensory and
autonomic neuropathic features rather
than the motor neuropathy classically
attributed to lead toxicity. It is proposed
that the traditional motor syndrome asso-
ciated with subacute lead poisoning is
more likely to be a form of lead induced
porphyria rather than a direct neurotoxic
eVect of lead.
(J Neurol Neurosurg Psychiatry 2001;71:200–204)
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Traditionally lead poisoning is described as
causing a purely motor disorder, often pre-
dominating in the arms and selecting heavily
used muscles, such as the wrist extensors of
painters.1–5 At presentation such patients usu-
ally have other systemic features such as colicky
abdominal pain, constipation, or anaemia.
Such disorders have tended to follow subacute
or acute high intensity exposure to lead.
Sensory abnormalities have not been a noted
feature of poisoning with lead, despite their
prominence in other heavy metal poisoning
neuropathies due to arsenic, mercury, or
thallium.6–8
Nerve conduction studies have been carried
out in chronically exposed industrial workers
with raised blood lead concentrations but no
clinical evidence of neuropathy.9–13 Neurophysi-
ology was normal in many, otherwise showing
minimally slowed motor conduction with
slightly reduced compound muscle action
potentials. These slight abnormalities tended
to improve once lead exposure ceased. Abnor-
malities of sensory nerve action potentials were
noted only in a few of these subjects, with
slowed conduction rather than reduced ampli-
tude.13 Sensory symptoms were generally
uncommon in these studies. Criteria for
diagnosing lead induced neuropathy have been
formulated1: (1) Demonstrable neuropathy on
clinical, pathological, or electrophysiological
grounds; (2) Involvement of another organ sys-
tem; (3) exposure corresponding in time to the
progression of the disease; removal from expo-
sure should result in stabilisation or remission;
(4) an increased tissue or body fluid content of
lead.
Confirmed lead induced polyneuropathy has
been extremely rare recently due to improved
occupational health. However, long term expo-
sure to lead occurred in industrial workers in
Latvia until the end of the 1990s. A large
cohort of such workers with increased lead
concentrations have been followed up14 and we
were struck by complaints of neuropathic
symptoms in nearly a third.
Subjects and methods
SUBJECTS
One hundred and fifty one subjects with raised
blood lead concentrations were registered in
Latvia (total population about 2.5 million) by
1998 on the state register of occupational
diseases; this represents about 70% of workers
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in lead risk occupations. The criteria for regis-
tration were firstly an occupational exposure to
lead and secondly increased blood or urine lead
concentrations, or both. The maximum bio-
logically safe lead concentrations in chronically
occupationally exposed persons are regarded as
40 µg/dl for blood and 5.0 µg/dl in 24 hour col-
lected urine.2 14 Additionally we measured
metabolites of haeme synthesis in urine:
ä-aminolaevulinic acid (ALA) (normal 0.5 to
2.5 mg/g creatinine), and coproporphyrins
(CPs) (normal 20–80 µg/g creatinine). All 151
patients underwent a clinical neurological
assessment in the occupational diseases clinic;
103 had no neuropathic symptoms or signs
suggesting polyneuropathy. The remaining 48
patients had features suggesting polyneuropa-
thy; we excluded patients with symptoms
suggestive of carpal tunnel syndrome (inter-
mittent finger sensory disturbance at night or
during manual work). These 48 were screened
for other causes of neuropathy by history and
routine blood chemistry, including blood
sugar; one with diabetes mellitus and one with
alcoholism were excluded from further analy-
sis.
BIOCHEMICAL ASSAY
All 151 subjects were investigated periodically,
including full blood count, reticulocyte counts,
examination for basophilic stippling of erythro-
cytes, urinary analysis, liver enzymes, and
ECG. The concentrations of lead in whole
blood and urine were determined by atomic
absorption spectrophotometry (Perkin Elmer
403 with graphite furnace HGA 2200) using a
deuterium background compensation
system.14–16 Coproporphyrins and ALA were
assayed as described previously.17 18
CLINICAL ASSESSMENT
Neurological examination of all 151 subjects
was performed yearly by OR. Limb power was
recorded as 0=normal, 1=minor symptoms or
signs, 2=incapable of work or independent
walking. Tendon reflexes were graded as
0=normal, 1=diminished ankle jerk compared
with other tendon reflexes, 2=absent ankle jerk.
Symptoms of paraesthesiae or pain distally in
the limbs were recorded as 0=absent, 1=mild
and intermittent, 2=continuous without inter-
ference with movement or sleep, 3=severe,
continuous, and intrusive, often needing symp-
tomatic therapy. Pinprick sensation was re-
corded as 0=normal, 1=blunted distally, 2=lost
distal pain sensation. Vibration sense was
tested at the metatarsophalangeal joints using a
standard camertone C128 tuning fork in 20
patients (normal>10 seconds). Coldness, skin
colour, and marmorisation or hyperhydrosis of
limb skin were recorded. Blood pressure was
tested in lying and standing positions in 20
patients. Involvement of other organ systems
was noted: mood or sleep disturbances, abnor-
mal liver or kidney function tests, hyper-
tension, gastrointestinal disturbance, and ab-
normal haematological indices.
ELECTROPHYSIOLOGICAL STUDIES
These were performed bilaterally once every 2
years in all 46 patients using “Neuropack-II”
(Nihon Kohden, Japan). Motor conduction
velocity (MCV) and distal motor latencies
(DMLs) were measured in median, ulnar,
peroneal, and tibial nerves. Sensory nerve
action potential latencies (DSLs) and ampli-
tudes (SNAPs) were measured in the median
and medial plantar nerves, averaging 60 stimu-
lus responses. Laboratory normal ranges are
shown in table 3.
Results
PATIENTS’ CHARACTERISTICS (TABLE 1)
Of the whole group of 151 workers with occu-
pational exposure and with raised lead concen-
trations, 46 (30%) had features corresponding
to the criteria for lead neuropathy. Of these 46
workers the mean age at presentation was 50
years and 65% were women. Their commonest
occupations were soldering, oxyacetylene cut-
ting of shipwrecks, and typesetting. Duration of
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Oxyacetylene cutters 4 (9%)
Enamel makers 3 (6.5%)
Battery workers 3 (6.5%)
Car paint workers 2 (4%)
Others 4 (9%)





























5–15 mm Hg 5 (25)
16–30 mm Hg 3 (15)




















occupational exposure ranged from 8 to 47
years (mean 21.7); most ranged from 11–20
years (46%) or 21–30 years (30%). First
neuropathic symptoms occurred between 7
and 45 years (mean 20.0 (SD 8.1)) after start-
ing occupational exposure. Further occupa-
tional exposure to lead had been stopped after
medical diagnosis of intoxication, on average
2.8 (SD 3.8) years before this study. Neuro-
pathic symptoms remained in all 46 after stop-
ping exposure, but in no case did symptoms
progress significantly.
LEAD AND PORPHYRIN CONCENTRATIONS (TABLE
2)
Blood and urinary lead concentrations in the
neuropathic patients were substantially raised
above the recommended safe maxima. Urinary
CPs were raised in 23 of 46 patients (50%),
urinary ALA in six of 46 (13%), but generally
only mildly. Both ALA and CP were raised in
three of 46 (7%). Neither blood nor urinary
lead concentrations correlated significantly
with CP or ALA concentrations (Pearson cor-
relation coeYcient). Lead and CP concentra-
tions are presented also for a group of patients
without neuropathic symptoms, with a similar
average duration of lead exposure. Blood and
urinary lead concentrations were about 25%
lower in these non-neuropathic subjects, but
their CP concentrations were similar to those
in the neuropathic group. It should be noted
that this group was generally less symptomatic
and therefore subject to less surveillance.
CLINICAL FEATURES OF POLYNEUROPATHY (TABLE
1)
Paraesthesiae and pain or impaired sensation
occurred to varying severity for all 46 neuro-
pathic lead intoxicated patients. Pain and
paraesthesiae always occurred in the feet, and
also in the hands in 26 (57%). Pinprick sensa-
tion on the feet or hands was always blunted.
The duration of vibration sensation at the
metatarsophalangeal joint was reduced to
between 0 to 8 seconds in the 20 who were
examined; both sides were symmetrically
aVected (right 3.2 (SD 1.7) seconds; left 3.1
(SD 1.9) seconds). Limb weakness and disabil-
ity did not occur in any of the patients. The
ankle tendon jerks were absent or reduced
compared with other tendon reflexes. Postural
hypotension of 5 to 15 mm Hg (systolic)
occurred in five (aged 43–66 years) and of>15
mm Hg in three (aged 48–55 years) of the 20
tested. Cold sensations in the distal limbs and
increased hand and foot sweating were noted
by most. Vasomotor changes aVecting skin col-
our were noted in the hands or feet of 21
(46%). Other organ systems were involved in
45 (98%): 44 (96%) had mood or sleep distur-
bances, 22 ( 48%) had arterial hypertension
(>140 mm Hg systolic, or>90 mm Hg diasto-
lic, or both), 13 (28%) from gastrointestinal
disturbances, and 19 (41%) had haematologi-
cal abnormalities (reticulocytosis, basophilic
stipling, or anaemia).
NERVE CONDUCTION STUDIES (TABLE 3)
Lead intoxicated neuropathic patients had, on
average, prolonged DMLs and distal DSLs,
with SNAP amplitudes at the bottom of the
normal range in all nerves studied. Motor con-
duction velocities and compound muscle
action potentials were normal. In four patients
disparities between median and ulnar DMLs
pointed to a superimposd carpal tunnel
syndrome, and in two disparities in tibial and
peroneal nerve conduction pointed to tarsal
tunnel entrapment. Otherwise, there were no
significant diVerences between the right and
left sides for nerve conduction indices in the
group as a whole (for example, median DML
right 4.78 (SD 0.21) ms, left 4.75 (SD 0.33)
ms; medial plantar SNAP right 4.83 (SD 0.26)
µV, left 4.66 (SD 0.30) µV).
CASE REPORT: ACUTE LEAD POISONING
A 45 year old man developed acute abdominal
pain and underwent laparotomy and appen-
dectomy, procedures which were uncompli-
cated. For at least 3 days his legs had been too
weak to stand, and his hands too weak for feed-
ing. On the fourth postoperative day he fainted
on standing. He had also noted a headache for
2 months. Colicky abdominal pain continued
Table 2 Average lead and porphyrin concentrations (mean (SD) (range)
Neuropathic group (n=46) Non-neuropathic group (n=46)
Recommended normal range
or maximum
Duration of exposure (y) 21.7 (8–47) 23.1 (1–51)
Blood lead (µg/dl) 63.93 (18.27) (40–144) 49.25 (12.84) (26–90.7) 40
Urinary lead (µg/dl) 9.0 ±3.0) (2—17) 6.0 ( 2.0) (1–12) 5.0
Urinary coproporphyrins (µg/g creatinine) 66.71 (38.41) (16.5–208) 62.14 (31.09) (15–176) 20–80
Urine aminolaevulinic acid (mg/g creatinine) 1.54 (0.39) (0.73–2.2) 1.61 (0.51) (0.14–2.83) 0.5–2.5
Table 3 Nerve conduction studies (mean ( SD))
Investigated
indices in nerves





















DML 4.78 (0.25) <4.4 3.78 (0.26) <3.4 6.31 (0.09) <5.8
MCV 52.6 (2.4) >45.0 49.1 (2.5) >45.0 51.0 (3.8) >45.0 41.0 (1.6) >42.0
CMAP 4.64 (0.56) >2.0 3.81 (0.51) >2.0 4.56 (0.62) >2.0 2.85 (0.31) >2.0
SNAP 5.2 (0.28) 4–15 4.75 (0.31) 4–12
DSL 5.12 (0.18) <4.4 6.23 (0.28) <5.6
DML=Distal motor latency (ms); MCV=motor conduction velocity (m/s); MAP=compound muscule action potential (mV); SNAP=sensory nerve action potential
(µV); DSL=distal sensory latency (ms).




















for 2 weeks. During the second week basophilic
stippling of erythrocytes was noted with a fall-
ing haemoglobin (138 g/dl to 112 g/dl over 8
days) and a raised urinary lead concentration
(9.0 µg/dl) was detected. Before this illness the
patient had worked for 3 years as an oxyacety-
lene cutter dismembering nine submarine
hulks which contained 30% lead, 4% molybde-
num, and traces of nickel, chromium, and
vanadium; the high lead content of submarine
hulls acts as a shock absorber. No ventilation or
breathing equipment was used. During the
month before this illness, his working practices
had not changed, he had not taken medicine,
and his alcohol consumption remained moder-
ate. Two months after presentation the blood
lead was 170 µg/dl (normal<40 µg/dl), 24 hour
urinary lead was 12.0 µg/dl (normal<5 µg/dl ),
urinary ALA 21 mkg/g creatinine (normal 0.5–
2.5 mkg/g), and urinary CPs 2102 mg/g creati-
nine (normal 20–80 mg/g). Intravenous chela-
tion therapy was started at 2 months with 16 g
EDTA (calcium disodium edetate). Appreci-
able limb weakness lasted 3 months. In
retrospect he had noted mild tingling and
numbness in his fingers and toes 2 weeks
before presentation and mood and sleep
disturbances which had continued intermit-
tently. Examination showed a bluish “lead line”
on the gums. Initial neurological examination
after 2 months showed diminished Achilles
tendon reflexes, stocking and glove reduction
of superficial sensation, markedly reduced limb
muscle strength, and hyperhidrosis of the
palms and feet. Nerve conduction studies 2.5
months after presentation showed a median
nerve DML of 5.2 ms, MCV 52 m/s, DSL 5.0
ms, and SNAP 6 µV. By 8 months after presen-
tation the blood lead was 58 µg/dl, urinary lead
4.0 µg/dl, urinary ALA 1.3 mg/g creatinine, and
urinary CP 34 µg/g creatinine. Examination at
21 months, when he still had limb pain and
stiVness, showed slight weakness of small hand
muscles, diminished ankle jerks, normal vibra-
tion and joint position sensations, distally
reduced pinprick sensation, and a 25 mm Hg
postural drop in systolic blood pressure.
Discussion
Our patients had an unusually long duration of
exposure to inorganic lead and showed neuro-
pathic features diVerent from those tradition-
ally attributed to lead toxicity. Their mild sen-
sory and autonomic polyneuropathy contrasts
markedly with the traditionally described pure
motor disorder, which particularly picks out
overused muscle groups such as the wrist
extensors. Only one previous study has re-
ported a high occurrence of sensory symptoms
(49%) with a low rate of weakness (11%) in
patients chronically exposed to lead but many
of those had been exposed to organic rather
than inorganic lead.19 Patients with lead intoxi-
cation with subacute motor weakness usually
improve after removal from a toxic source as
was the case in our sole patient with a subacute
motor disorder. By contrast we found no
evidence that sensory neuropathic patients
with chronic lead exposure improved during
their first years after stopping exposure. Nota-
bly, their blood and urinary lead concentra-
tions remained increased 4 years after removal
from exposure, despite chelation therapy;
elimination of lead from bone takes decades.
Presumably this bone storage constituted a
continuing endogenous source of lead toxicity
to the nervous system. Many of our chronically
exposed patients showed toxic eVects on other
body organs, such as the brain, cardiovascular
system, gastrointestinal tract, and red blood
cells.
No previous studies have reported on the
neuropathic consequences of such long term
exposure to inorganic lead. Previous studies of
exposed workers with raised lead concentra-
tions have not noted clinical neuropathic
abnormalities, despite mild electrophysiologi-
cal abnormalities.9 12 13 However, those popula-
tions were much younger than ours and their
mean duration of exposure, if recorded, was
only 4.6 years12 compared with the average of
21.7 years for our patients. Thus, the potential
for lead to damage directly the peripheral
nervous system was substantially higher in our
patients than in those reported previously.
More direct comparison of the intensity of lead
exposure between diVerent studies is impossi-
ble. In particular there is no method for time
averaged quantification of the concentration of
lead in inhaled fumes during occupations such
as metal cutting or lead smelting, or of oral
ingestion because of poor hand cleaning.
Undoubtedly many of our patients had been
exposed to notably high densities of fumes or
dust in poorly ventilated circumstances, and
often with inadequate hand cleaning proce-
dures. For instance the workplace lead concen-
trations found in 14 patients exceeded recom-
mended maximum acceptable concentration
values by 1.2-fold to threefold in the air
(normal<0.1 mg/m3), and by 670-fold in the
“protective” work clothes in two lead paint
sanders and polishers. Most previously studied
exposed workers have been men. The predomi-
nance of women in our neuropathic group
simply represents their high representation in
this working population rather than any
particular female susceptibility to lead neu-
ropathy; 65% of the polyneuropathy group
were women compared with 57% of the group
exposed to lead without polyneuropathy.
Previous electrophysiological studies have
concentrated on groups of workers exposed to
lead but generally free from neuropathic symp-
toms, or on those occasional patients with sub-
acute motor weakness associated with lead tox-
icity. Minor changes in distal motor nerve
conduction or CMAP amplitudes have been
noted when the level of safe chronic occupa-
tional exposure was exceeded.1 9 10 12 13 Our
patients showed similar mild abnormalities of
motor conduction without clinical motor
abnormalities. Sensory nerve conduction has
been studied less often in lead exposure.
Abnormalities of SNAP amplitude have not
been reported, but slight slowing of sensory
conduction has.13 Likewise, sensory conduc-
tion velocity was slightly prolonged in the
median and tibial nerves of our patients,




















whereas the SNAP amplitudes were not
diminished on average, although they were
generally towards the bottom of the normal
range. Sensory nerve action potentials measure
the integrity of the fastest conducting large
myelinated fibres. The relative normality of
sensory conduction in our patients comes as
little surprise given that it does not measure
conduction along unmyelinated fibres, mediat-
ing sensations such as pinprick, which were
those predominantly aVected in our patients.
Further support for the notion of involvement
of predominantly unmyelinated fibre comes
from our finding of autonomic abnormalities
aVecting limb skin and of postural hypoten-
sion. Occasionally electrophysiology showed
coexisting carpal tunnel syndrome, of little
surprise in this population of manual workers
and noted previously.19
It is likely that two diVerent neuromuscular
syndromes can result from lead intoxication: a
subacute predominantly motor syndrome and
a chronic sensory and autonomic syndrome.
Do these two lead induced syndromes have a
diVerent pathogenic basis? Electrophysiology
provides little clue as studies of the subacute
motor presentation largely antedate modern
measurement of nerve conduction and mainly
report denervation on EMG.4 20 In our sole
patient with subacute motor weakness after
high intensity short term lead exposure,
studied 2 months after presentation, the distal
motor latencies were mildly prolonged, motor
conduction velocity was normal, and sensory
conduction was slightly slowed. Surprisingly,
these findings diVer little from those in chroni-
cally exposed patients who are asymptomatic
or who had mild sensory and autonomic
features. The striking diVerence was the
massive increase in porphyrins in our patient
with subacute motor neuropathy compared
with the inconsistent and generally insignifi-
cant porphyrin increases seen in our patients
chronically exposed to lead with mild sensory
and autonomic neuropathy. Relatively little is
known about the pathogenesis of subacute
muscle weakness in attacks of porphyria, the
general consensus pointing to axonal
degeneration.21–24 However, porphyric muscle
weakness usually recovers more rapidly than
would be accounted for by axonal regenera-
tion, and possible impairment of muscle energy
metabolism during porphyric attacks has not
been investigated. Lead intoxication is known
to cause multiple abnormalities of porphyrin
metabolism.25 Furthermore, plumboporphyric
muscle weakness occurs in the context of nor-
mal lead concentrations in those rare patients
with ALA dehydrase deficiency.26
We conclude that lead intoxication may
aVect the neuromuscular system in two diVer-
ent ways. Firstly, the subacute predominantly
motor syndrome traditionally associated with
high dose lead intoxication is probably second-
ary to lead induced porphyria. Secondly, our
patients with extremely long term lead intoxi-
cation manifested a mild sensory and auto-
nomic polyneuropathy which probably reflects
a direct neurotoxic eVect of lead. Fortunately,
future opportunities will be limited for study-
ing the pathogenesis of neuromuscular diseases
associated with lead intoxication given the
introduction of extensive health and safety
controls on workplace exposure.
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